Avastin-Injections in Age Related Macular Degeneration:<br>Prospective Study for Optimal Frequency and Follow-up Determination.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Exudative Age Related Macular Degeneration (ARMD).
- Sponsor
- Oogziekenhuis Rotterdam, Schiedamsevest 180, 3011 BH Rotterdam
- Enrollment
- 360
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
ushchyk T, Amarakoon S, Martinez-CirianoJP, van den Born LI, Baarsma GS, Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. Acta Ophthalmol. 2013; 91(6): e456-461. PMID: 23773796 Amarakoon S, Martinez-Ciriano JP, van den Born LI, Baarsma S, Missotten T. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks. Acta Ophthalmol. 2019; 97(1): 107-112. PMID: 30369062 Visser MS, Amarakoon S, Missotten T, Timman R, Busschbach JJV. Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial. Qual Life Res. 2020 [Epub]. PMID: 32666333
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Informed consent;
- •2\. Endophthalmitis risks have been made clear;
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified